# Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

> **NCT01802073** · PHASE3 · COMPLETED · sponsor: **Stanford University** · enrollment: 34 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Oral Vancomycin

## Key facts

- **NCT ID:** NCT01802073
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802073, "Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01802073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*